(Cervical Cancer) Libtayo (Cemiplimab) Launched in Japan for Recurrent/Progressive Disease
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
- March 30, 2023
- 1 min read
On March 30, 2023, Sanofi Japan announced the commercial launch of Libtayo (cemiplimab) IV infusion, an anti-PD-1 antibody drug, for the treatment of cervical cancer that has progressed or recurred following chemotherapy.
Cervical cancer is most commonly caused by HPV infection. Approximately 80% of cases are squamous cell carcinoma, with the remainder being primarily adenocarcinoma. Treatment options are limited for patients with progressive or recurrent disease.
This approval is based on the EMPOWER-Cervical 1 Phase 3 clinical trial, an international multicenter study enrolling patients (N=608) with recurrent or metastatic cervical cancer. Patients were randomized to receive Libtayo (350 mg every 3 weeks as second-line therapy, N=304) or investigator's choice of chemotherapy (N=304). The primary endpoints were overall survival (OS) and progression-free survival (PFS).
Key Results:
- Median OS: Libtayo 12.0 months vs. chemotherapy 8.5 months — statistically significant improvement
Sanofi Japan stated that the company will continue to collaborate with co-developer Regeneron to bring hope to cervical cancer patients in Japan, and to further contribute to patients, families, and healthcare providers.
Source: https://www.sanofi.co.jp/dam/jcr:0a6fdb34-9135-4f48-9c4a-ff178bcb58fc/230330.pdf
Cervical Cancer | Immunotherapy | Libtayo | Cemiplimab
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4